Analysis of V beta 8.2 CDR3 sequences from spinal cord T cells of Lewis rats vaccinated or treated with TCR V beta 8.2-39-59 peptide.
Experimental autoimmune encephalomyelitis (EAE) in the Lewis rat can be induced with the administration of Gp-BP. This disease appears to be mediated at least in part by V beta 8.2+CD4+T cells, which specifically recognize the BP72-89 encephalitogenic peptide. Treatment or protection with V beta 8.2 CDR2 39-59 peptide can suppress or prevent clinical signs of EAE, presumably through the activation of regulatory T cells. Interestingly, V beta 8.2+ T cells continue to persist in the spinal cord of protected animals, although their appearance in the central nervous system (CNS) is delayed when compared with control animals with EAE. As part of our effort to elucidate the mechanism(s) of peptide protection and therapy, we sought to determine whether the V beta 8.2+ T cells in the spinal cord of protected or treated rats were truly representative of those found in rats with clinical EAE. Therefore, we examined the following CNS samples for the Asp96Ser97 motif, which has been identified previously in V beta 8.2+ BP-specific, encephalitogenic T cell clones: 1) rats protected with V beta 8.2-39-59 peptide, 2) rats treated with V beta 8.2-39-59 peptide, and 3) control rats with EAE. Our findings indicate that EAE-associated V beta 8.2+ sequences can still be found in both peptide-treated and peptide-protected rats. It appears that administration of V beta 8.2 CDR2 peptide does not prevent EAE-associated V beta 8.2+ T cells from infiltrating the CNS and that other mechanisms are at work to prevent the development of EAE.
Buenafe
A C
AC
Veterans Affairs Medical Center, Portland, OR 97201, USA.
Vainiene
M
M
Celnik
B
B
Vandenbark
A A
AA
Offner
H
H
D000595:Amino Acid Sequence; D000818:Animals; D001327:Autoimmune Diseases / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control / Q000628:therapy; D001483:Base Sequence; D015496:CD4-Positive T-Lymphocytes / Q000737:chemistry* / Q000276:immunology; D018076:DNA, Complementary / Q000235:genetics; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control / Q000628:therapy; D005260:Female; D015333:Gene Rearrangement, beta-Chain T-Cell Antigen Receptor; D007167:Immunotherapy; D008213:Lymphocyte Activation; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use; D051381:Rats; D011917:Rats, Inbred Lew; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000235:genetics / Q000276:immunology*; D013116:Spinal Cord / Q000276:immunology* / Q000473:pathology; D016176:T-Lymphocyte Subsets / Q000737:chemistry* / Q000276:immunology; D014611:Vaccination
D018076:DNA, Complementary; D010446:Peptide Fragments; D016693:Receptors, Antigen, T-Cell, alpha-beta